NOT TRANFERABLE



TENDER NO.:- BPPI/Drugs&SurgicalTesting/048-2017

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS MEDICINES & SURGICAL FOR 2017-2019

Dated: 02.03.2017



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)
IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON 122016
Telephone: 0124-4303751/56; Fax: 0124-2340370 Website: janaushadhi.gov.in

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI) (SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003 Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR **ANALYSIS OF DRUGS & MEDICINES FOR 2016-2018**

Important Dates:	
Tender Reference Number	BPPI/Drug & surgical Testing/048-2017
	Date 09/03/2017
Date of availability of Tender	09/02/2017 (Thursday)
documents on website	
Last date and time for receipt of	02/03/2017 (Thursday)15.00 hrs
Tender	
Date and time of Opening of	02/03/2017 (Thursday)15.30 hrs
Tender	
Place of Opening of Tender	BPPI, IDPL Corporate Office, IDPL
	Complex, Dundahera, Gurgaon (HR)
Address For Communication	BPPI, IDPL Corporate Office, IDPL
	Complex, Dundahera, Gurgaon (HR)-
	122016
Contact Person for clarification i	f any:
1. Ms. Reena Bhagat	2. Mr. Mahadev Agarwal,
Dy. Mgr(Quality and Regulatory)	Manager (Procurement)
Phone: 0124-4040768	Phone: 0124-45567554
Mob: 8130704311	Mob: 9873294473
Email:reg2.bppi@gmail.com	Email: mahadevpharm.bppi@gmail.com

CONTENTS

Sl. No.	Description	Page No.
1	Last date for receipt of tender	04
2	Eligibility criteria	04
3	Technical bid – Cover - 'A' including Earnest Money Deposit & other	05
	Documents	
4	Price bid – Cover - 'B'	06
5	General conditions	07
6	Acceptance of tender(Opening of Cover -'A' and Cover-'B' of tender)	07
7	Agreement	08
8	Security Deposit	08
9	Complete Analysis and Reporting Condition	08
10	Payment Provisions	10
11	Penalties Provisions	10
12	Black Listing Procedure	10
13	Agreement Format	11-14
14	Annexure-I : Performa for Performance Statement	16
15	Annexure –II: Details of Laboratory and Certificate of Registration for	17
	Service Tax	
16	Annexure-III (A) Personnel in Laboratory	18
17	Annexure-III (B) List of Sophisticated Instruments	18
18	Annexure-III (C) Facilities in Microbiological Section	19
19	Annexure-IV: Declaration Form	20
	Annexure VA: List of DRUGS	
20	Annexure VB : List of Surgical	21-25
21	Annexure VI Declaration as per para 2(e) &5 vi	26
22	Annexure VII : Checklist	27
23	Annexure VIII : Cover - 'B' (Price bid) in a separate cover	28

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under Department of Pharmaceuticals, Govt. of India)

TENDER FOR EMPANELMENT OF DRUGS & SURGICAL TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR BPPI FOR TWO YEAR (2017-19) FROM THE DATE OF ACCEPTANCE OF TENDER

"CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER"

1. Sealed tenders are invited till 02/03/2017 Thursday(15.00 hours) by CEO BPPI at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), (Herein referred as Tender inviting authority unless the context otherwise requires) for empanelment of approved drug testing laboratories (under Drugs & Cosmetics Act 1940 & Rules 1945) which are GLP compliant (as per Schedule L1) and NABL accredited for drugs requiring Chemical/Physicochemical, instrumental and microbiological testing facilities for a period of two years from the date of acceptance of tender by BPPI. The agreement may be extended for further period on mutually agreed terms.

The complete set of tender document can be downloaded from the BPPI website **janaushadhi.gov.in** and **CPP portal i.e eprocure.gov.in** free of cost.

NOTE:- LATE TENDER IS NOT ACCEPTABLE

2. Eligibility Criteria:

- (a). National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited analytical laboratories having approval/license under the Drugs and Cosmetics Act and Rules 1945 with minimum two years experience in the analysis of DRUGS & MEDICINES with an minimum average annual turnover of Rs. 30 Lakhs for last two years i.e 2014-15and 2015-16 (Govt./CPSU's Laboratories, Research and Development Laboratories, Laboratories run by Co-operative body and Educational Institutions are exempted from the turnover criteria) however turnover for the year 2014-15 should not be less than Rs. 30 lakhs, are eligible to participate in the tender. Agents are not eligible to participate in the tender.
- (b). Drug Testing Laboratory which is also engaged in manufacturing of medicines and participate in drug procurement as well as drug testing Laboratory tender shall not be considered for testing laboratory empanelment as eligible if their product achieve L-1 rate in any drug procurement tender by BPPI.
- (C). Drug Testing laboratories should have Approval/ license under Drugs & Cosmetics Act and Rules 1945, with two years standing in the analysis of Drugs & Medicines.

- (d). Drug Testing laboratories should be GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 and should hold Schedule L1 certificate.
- (e). Drug Testing laboratories should not have been banned/debarred/ black listed/deregistered by any State or Central Govt. Organizations or its procurement agencies on the due date of bid submission.
- (f). Drug Testing laboratory and its responsible persons should not have ever been convicted under the D & C Act 1940 and Rules 1945.
- (g). Drug Testing laboratory should have all necessary instruments/equipments and required mandatory facilities for testing/analysis of Drugs and Medicines as per statutory requirement for which it is participating in the tender.
- (h) Attested copy of approval and GLP Certificate of Drug Testing laboratory, duly renewed up to date issued by the state licensing authority be submitted.

3. Technical bid – Cover -'A' including Earnest Money Deposit & other Documents:

The tenderer must submit the following documents in the sealed cover super scribed **Cover -'A'** (all the documents have to be sealed and copies have to be self attested and notarized in all pages).

[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-(Rupees Ten Thousand only) paid in the form of **Demand Draft or Banker Cheque drawn** in favour of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Delhi/Gurgaon, should be sent with tender form in Cover- 'A'. The EMD is refundable however it will not earn any interest. EMD in the form of cheque/ cash/ postal order/ e-payment will not be accepted.

The EMD amount of unsuccessful bidder will be refunded to them within 30 days of finalization of tender. In respect of successful bidder (empanelled bidder), the EMD amount will be adjusted towards security deposit.

- **[b].** Self attested and notarized photocopies of Approval/ license issued by State Licensing Authority duly renewed up to date and NABL accreditation certificate.
- [c]. Documentary evidence of having analyzed DRUGS & Surgical for the last two years with the statement in the performa given in Annexure-I
- [d]. Self attested and notarized photocopy of certificate of registration for Service Tax should be enclosed in Annexure-II.
- [e]. Non conviction certificate issued by State Licensing Authority (SLA)/Competent Authority which should not be 6 months old on date of submission of bid.

- [f]. Self attested and notarized document of the following should be furnished in the format given in Annexure-III
 - (i). List of qualified personnel employed in Drug Testing laboratory along with their qualification, experience and details of their approvals (copy of the approval).
- (ii). List of sophisticated instruments (working condition) available in Drug Testing laboratory.
 - (iii). Facilities available in Microbiological Section in the laboratory
- **[g].** A declaration in the Performa given in Annexure-IV duly signed and notarized.
- [h]. Details of DRUGS & Surgical to be analyzed to be given in Annexure-VA & VB
- [i]. Documentary evidence regarding constitution of Drug Testing laboratory viz. Memorandum and Articles of Association, partnership deed etc, with details of name, address, telephone no., fax no., e-mail address of Managing Director/ Partner/ Proprietor etc.
- **[j].** The instruments such as power of attorney, Resolution of Board etc authorizing the tenderer, should be enclosed in the tender (in Cover-'A') duly signed by authorized signatory of the Drug Testing laboratory. Such authorized signatory of the tenderer should sign at the bottom of all the pages of the tender documents.

OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]

- (k). Annual turnover statement certified by the auditors (C.A.) for last two years i.e., <u>2014-15 and</u> 2015-16.
- (1). Tenderer shall submit the checklist of documents in the enclosed performa in Annexure –VII

4. PRICE BID (COVER-'B')

- (a). Price Bid (Annexure VIII) of the tenderer duly filled in giving the rate of testing, charges for complete testing of each sample and signed on each page by authorized person with company seal, should be sent in separate sealed cover indicating name of the tenderer and superscribing "Price Bid" Cover 'B' hereafter called Cover-'B'.
- **(b).** Cover-'B' shall contain the rates quoted by the tenderer only. It shall not contain any other document. No condition shall be indicated in the price bid. All the terms and conditions shall be indicated only in the technical bid.
- (c). The tender documents and certificates must be submitted in a separate sealed cover as Cover-'A' and Price Bid shall be kept in separate sealed cover as Cover-'B'. Both Cover-'A' and Cover-'B' shall be kept in single sealed cover on which it shall be superscribed as "TENDER FOR

EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & Surgical FOR TWO YEARS (2017-2019)

- (d). The tender document should reach Manager (A&F), BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), till 02.03.2017 by 15.00 hour.
- (e). If the last date of submission is declared holiday, the tenders may be submitted on next working day upto 10.30 A.M.
- (f). Tenderers should also enclose soft copy of Price Bid in CD along with Cover'B'

5. GENERAL CONDITIONS

- **i.** Forms in all annexure should be filled up properly. Every correction should invariably be attested by tenderer, failing which the tender will be summarily rejected.
- **ii.** The tenderer should quote the rates for complete analysis as per the pharmacopoeial or other standards as per provisions of Drugs and Cosmetics Act 1940 for each drug and medicine not for individual test to be performed.
- **iii.** The rates should be exclusive of taxes.
- **iv.** The rates quoted and accepted will be binding on the tenderer for stipulated period and on no account any revision will be entertained till the completion of the contract period.
- **v.** If in any circumstances (like breakdown of instrument or non-availability of reference standard and impurities etc.) the Drug Testing Laboratory is unable to test sample of Medicines, the same should be reported within 24 hours from time of breakdown of instrument or non-availability of reference standard of such sample by fax/e-mail to Dy. Manager Quality & Regulatory.
- **vi.** The tender submitted by the laboratory which has been banned/debarred blacklisted/deregistered by the State / Central Govt. organization, shall not be considered.(Annexure VI)
- vii. The laboratory will not be permitted to outsource any test from other Drug Testing laboratory.

6. ACCEPTANCE OF TENDER

- i. Out of two covers submitted by each tenderer, Cover- 'A' will be opened first at 15.30 hours on 02/03/2017 in the presence of tenderers or their authorized representatives who chooses to be present. After scrutiny of the documents and information furnished in Cover-'A' and confirmation of details stated therein, a list of eligible laboratories will be shortlisted.
- **ii.** Cover-'B' (Price Bid) of the tenderers found eligible on the basis of scrutiny of Cover-'A' will be opened subsequently and the date and time for opening of Cover-'B' will be intimated to the

shortlisted tenderers. The acceptable rates for analysis will be decided on the basis of L1 rates and will be communicated.

- **iii.** The tenderers other than L1 tenderer will be given opportunity to match L1 rate and after due confirmation, their name/s will be included in the panel. If required, the empanelled laboratories will be inspected by team of officials of BPPI as and when need arises. In case sufficient Laboratories are not empanelled due to any reason, BPPI reserves right to float fresh tender during period of two years.
- **iv.** The tender inviting authority, BPPI reserves the right to accept or reject any tender for any one or more of the items tendered for, without assigning any reason.
- **v.** No tenderer will be allowed to withdraw their bid after opening of Price Bid.

7. AGREEMENT

All tenderer who are empanelled will have to execute an agreement on non-judicial stamp paper of Rs. 100/-(stamp duty to be paid by tenderer) in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA within 15 days from the date of intimation received by them from BPPI that their tenders have been accepted. The form of agreement is available under para13 of tender document.

8. SECURITY DEPOSIT

The successful tenderers must pay a security deposit of Rs. **20,000**/-(Rupees Twenty Thousand only) including adjustment of EMD amount at the time of execution of agreement referred in Para 7 above by way of DD or Banker Cheque in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon.

9. COMPLETE ANALYSIS AND REPORTING CONDITION

- (a). On empanelment and entrustment of the job, the Drug Testing Laboratory should furnish the test reports within,
- (i). 8 days of receipt of sample in case of Tablet, Capsules, Ointment, Cream, Gel, Powder and Liquid oral preparations (all non-sterile dosage forms).
- (ii). 21 days of receipt of sample in case of LVP/SVP, Inject able in vial/Ampoules and Dry Powder Injectable (all sterile dosage forms).
- (iii). Within 24 hours of receipt of sample, the confirmation of receipt should be given to BPPI by fax / mail.

- (iv). For any delay more than stipulated time as mentioned in para 9 (a)(i) and (ii) as the case may be, 5% of testing charges per week and the part thereof would be deducted as penalty. For consecutively delay for 4 times or more than 8 times in a year or a delay of more than 10 days occurs over the time period stipulated above, then the penalty would be 10% of testing charges per week and part thereof.
- **(b).** All the test mentioned under IP, BP, USP and any other standard mentioned as per Second Schedule of under D& C Act 1940 and Rules 1945 as well as Schedule V should be carried out for each and every sample. The results obtained in the test should be mentioned in figures. Test reports not mentioning complete details as per IP, BP, and USP etc will be considered as "Incomplete test report" and the drugs testing laboratory will have to submit complete report for acceptance.
- (c). "Complies" or "Passes" or "Within Limit" in result column of the test report will also be treated as incomplete test report, if the result has some value the actual value found on analysis is to be reported.
- (d). Every test report must have some specific remarks as 'Standard Quality', or 'Not of Standard Quality.' Any ambiguity/ cutting will not be accepted.
- (e). Test report should have Sr. No., Description of tests, Specifications and Results obtained including protocol of test applied.
- **(f).** Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be attached with the test report.
- (g). In the case of non-pharmacopoeial products the method of analysis should be mentioned in the report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT,
- (h). The test report should be sent to Dy. Manager (Quality & Regulatory), BPPI office as hard copy and simultaneously scanned copy should be sent by e-mail reg2.bppi@gmail.com.
- (i). All test report should be submitted to BPPI in duplicate. In case of failure of sample, result should be communicated immediately toDy. Manager (Quality & Regulatory), BPPI through phone/ fax/ e-mail and physical report should be sent with covering letter addressed to Manager (Regulatory) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana).
- (j). If in any circumstances (like breakdown of instrument or non-availability of reference standard etc.) the Drug Testing Laboratory is unable to undertake sample, the same should be reported within 24 hours of receipt of such sample by fax/e-mail to Dy Manager Regulatory and sample should be returned to him immediately. 100% of charges as penalty will be imposed in case no prior information of breakdown of instrument or non-availability of reference standard before sending samples. Refer para (5)(v).
- (k). If any sample is received in damaged condition by the laboratory, the sample should not be analyzed and should be sent back immediately to Dy. Manager (Quality and Regulatory), BPPI and due information should be given by fax/e-mail.

(l). Dy. Manager (Quality and Regulatory), BPPI or authorized representatives have the right to inspect the laboratories of the tenderer who have submitted tenders before taking any decisions regarding empanelment. He/She may also inspect any laboratory which is empanelled at any time during continuance of tender and initiate action to terminate / cancel its empanelment and not to entrust any further testing job to the laboratory if any violation of tender conditions are noticed during such inspections.

10. PAYMENT PROVISIONS

- i. No advance payment towards any analysis will be made to tenderer.
- ii. No payment will be made for incomplete analysis or incomplete report. Refer Para 9 (b) to 9 (g)
- **iii.(a).**Payments towards the analysis of DRUGS & MEDICINES & Surgical will be made along with tax at the prevailing rate as applicable at the time of payment strictly as per rules
- **(b).** Bills should be supported with the copy of test report. Efforts will be made to make payments within 30 days from the date of receipt of the bills by BPPI if same are found in order in all respect.

11. PENALTIES PROVISIONS

If the successful tenderer fails to execute the agreement and payment of security deposit after opening of Price Bid within the specified time or withdraws the tender after the intimation of acceptance of tender has been received by them or owing to any other reasons, the tenderer is unable to undertake the contract, the empanelment will be cancelled and security deposit shall stand forfeited to BPPI. Such tenderer will also be liable for all damages sustained by BPPI by reasons of breach of tender conditions. Such damages shall be assessed by CEO, BPPI whose decision shall be final.

12. BLACK LISTING PROCEDURE

- (a). Non performance of any tenderer or empanelment conditions will disqualify a laboratory to participate in the next tender.
- **(b).** To assess the correctness of the test results given by the empanelled Drug testing laboratory, samples would also be taken and sent randomly to Govt. laboratory/ CPSUs Laboratories/ any other NABL accredited labs which are not empanelled for testing and if any variation in the results is found, the result would be informed to empanelled laboratory. If there is any major variation in the analytical reports furnished by empanelled laboratories, (either pass or fail etc.) viz-a-viz Govt. /CPSUs Laboratory/ any other NABL accredited labs, the empanelled laboratory will be blacklisted for two years besides forfeiture of security deposit, after giving due opportunity to the concerned laboratory.
- (c). If it is revealed that Drug Testing Laboratory is involved in any form of fraud and collusion with the suppliers of BPPI, the Drug Testing Laboratory will be black listed for five years. The

tenderer shall also be liable for action under criminal law and matter will be informed to relevant appropriate authorities for penal action against them.

(d). The CEO, BPPI will be at liberty to terminate the empanelment without assigning any reasons. The tenderer will not be entitled for any compensation whatsoever in respect of such termination.

Note:

- In all matters pertaining to tender, the decision of CEO, BPPI shall be final and binding.
- In event of any dispute arising out of tender, such dispute would be subject to the jurisdiction of civil court within Delhi.
- In case of dispute or difference arising between BPPI and empanelled Drug Testing Laboratory relating to any matter arising out of or connected with this tender agreement, such dispute or differences shall be settled in accordance with the Arbitration and Conciliation Act 1996. The venue of arbitration shall be Gurgaon.

13. AGREEMENT FORMAT

(Contract for Empanelment of Drugs & Surgical Testing Laboratories for the Analysis of DRUGS & Surgical)

7AGREEMENT MADE at	this	day of	201 7at BPPI
Gurgaon between M/s1	naving its registered of	fice at	(hereafter referred to as 'The
Laboratory' which term shoul	d include its succes	ssors, represen	ntatives, hires, executors, and
administrators unless excluded b	by contract) on FIRST	PART and E	Bureau of Pharma Public Sector
Undertakings of India, set up	under Department of	Pharmaceutic	cals, Ministry of Chemicals &
Fertilizers, Government of India	as a Society register	ed under the s	ocieties registration act XXI of
1860, having its Registered Office	ice at Core No. 06, 15	st Floor, SCOI	PE Complex, Lodhi Road, New
Delhi - 110003, through Mr	S/o	,	hereinafter referred to
as "BPPI" (which expression sl	hall mean and include	its successor	s and assigns) of the SECOND
PART.			

WHEREAS the Laboratory has awarded a contract by BPPI to provide report and undertake the analytical work of the BPPI, (the list of medicines mentioned in the Schedule attached hereto Annexure-I and Annexure-II) at the rates noted therein and in the manner and under the terms and conditions hereinafter mentioned.

And whereas the Laboratory has deposited a sum of Rs 20000/- (Rupees Twenty thousand only) as Security Deposit for the due and faithful performance of this Agreement with the BPPI, which shall be forfeited in the event of the Laboratory's failure in performing its duties faithfully.

Now these presents witness that for carrying out the said Agreement in this behalf into execution, The Laboratory and the BPPI do hereby mutually convenient, declare, contract and agree each of them with the other of them in the manner following, that is to say,

(1). The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions in tender floated by the BPPI for Empanelment of Drugs Testing, laboratories for the analysis of DRUGS & MEDICINES for the two years 2016-2018 the instructions to tenderer, the conditions of tender, acceptance of tender particulars hereinafter defined and those general and special conditions that may be added from time to time.

GENERAL TERMS & CONDITIONS:

(2). (a). The Agreement is for undertaking analysis of DRUGS & Surgical by the Laboratory to the
BPPI of the samples specified in the Schedule attached hereto Annexure-I and Annexure-II at the
rates noted against each therein on the terms and conditions set forth in the Agreement.

(b).	This Agreement shall be deemed to have come into	force with effect from
and it	shall remain in force for a period upto date of	and may however be extended
for a fu	urther period, on mutually agreed terms.	

- (c) Laboratory shall perform services with care, skill, and diligence, in accordance with the applicable professional standards currently recognized by such profession, and shall be responsible for the professional quality, technical accuracy, completeness, coordination, and timeliness of all items and services furnished under this Laboratory Agreement.
- (d) Laboratory shall comply with all applicable NATIONAL, state, and local laws, ordinances, codes, and regulations in performing services. If Laboratory fails to meet applicable professional standards, Laboratory shall, without additional compensation, correct or revise any errors or deficiencies in items or services furnished under this Agreement.
- (e) Laboratory shall retain, at a minimum, accreditation to ISO/IEC as per rules granted by a national accreditation body. Laboratory shall notify BPPI immediately if accreditation is in jeopardy or lost. Upon BPPI's request, Laboratory shall present BPPI with proof of its accreditation.
- (f) For all requests made by BPPI pursuant to this Agreement, time is of the essence. The acceptance of a late performance, with or without objections or reservations by BPPI, shall not waive the right to claim damages for such breach nor constitute a waiver of the requirement of timely performance of any obligations remaining to be performed.
- (g) In accordance with the ASTM Standard, all required tests shall be conducted to completion.

INSPECTION OF LABORATORY:

(3) In respect of the analysis medicines in the Schedule, the drug testing Laboratory shall allow inspection of the Laboratory at any time during the tender period by a team of Experts/Officials whom the BPPI may depute for the purpose. The Laboratory shall extend all facilities to the team to enable them to inspect premises, testing faculties, technical personals, reference standards/ working standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory.

RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:

(4). All expenses, damages and other money payable to the BPPI by the drug testing Laboratory under any provisions of this Agreement may be recovered from the amount due or subsequently becoming due from the BPPI to the Laboratory under this or any other Agreement. In case such amounts are insufficient to fully cover such expenses, damages or other money payable, it shall be lawful for the BPPI to recover the balance amount from the security deposit of the Laboratory and all other money held by BPPI and in case such Security Deposit is insufficient, then it shall also be lawful for the BPPI to recover the residue of the said expenses, damages and moneys, if necessary, by resorting to legal proceedings against the Laboratory.

AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:

(5). The Laboratory shall deposit with the BPPI Rs. 20,000/- as security deposit by way of Demand Draft favoring BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon. This agreement comes into effect only after the laboratory has remitted the required amount of security deposit, not withstanding anything contained in Para 2 (b) of this agreement.

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:

- (6). (a). No advance payment towards any analysis will be made to the Laboratory.
- (b). All bills/invoices should be raised in duplicate in the name of BPPI. All payments shall be made by way of cheque drawn in favour of Laboratory account and Crossed Account Payee / NEFT only. The Laboratory shall furnish the details of their bank account no., name of bank and branch, IFSC code no. etc to the BPPI. (An original cancelled cheque leaf issued by their bank should be furnished).

ASSIGNMENT OF CONTRACT PROHIBITED:

(7). The Laboratory shall not, at any time, assign, sub-let or make over the present contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

TERMINATION OF CONTRACT ON BREACH OF CONDITION:

- (8).(a). In case the Laboratory fails or neglects or refuses to faithfully perform any of the covenants on his part herein contained or violates the condition in the tender document, it shall be lawful for BPPI to forfeit the amount deposited by the laboratory as security deposit and cancel the contract apart from black listing the laboratory for period of two years.
- **(b).** In case of laboratory fails or refuses to observe, perform, fulfill and keep all or any other or more or any part of anyone of covenants, stipulations and provisions herein contain, it shall be lawful for BPPI on any such failure, neglect or refusal to put an end to this agreement and there upon every article clause and thing herein contained on the part of BPPI shall cease and be void and in case of any damage, loss, expense, differences in the cost or other moneys than or any time during the continuance of this agreement becoming due or owing by the laboratory to BPPI, it will be opened

for BPPI to recover from laboratory all such damages, losses, expenses, differences in cost or other moneys as aforesaid it shall be lawful for BPPI to appropriate the security deposit made by laboratory as herein before mentioned to reimburse all such damages, losses, expenses differences in cost and other moneys as BPPI have sustained, incurred or put to by reason of the laboratory having seen quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of contract.

- (c). If at any time during the course of contract it is found that information given by the laboratory to BPPI, either in tender or otherwise, is false, BPPI may put an end to contract / agreement wholly or in part and thereupon the provisions of cause (a) shall apply.
- (9). The BPPI reserves its right to terminate without assigning any reasons therefore the contract/agreement either wholly or in part without any notice to the laboratory. The laboratory will not be entitled for any compensation whatsoever in respect of such termination of contract by BPPI.

INDEMNIFICATION

- (10) Laboratory will hold BPPI harmless and indemnify BPPI for any claim arising:
 - (1) from Laboratory's noncompliance with applicable governmental laws or regulations,
- (2) from injury to Laboratory personnel while performing Laboratory's duties under this Agreement, and
- (3) in any manner from the services to be performed under this Agreement and caused by Laboratory's acts or negligence.

NOTICES ETC., IN WRITING:

(11). All certificates or notices or orders for the time or for extra, varied or altered laboratory, which are to be the subject of extra or varied charges whether so described in the agreement or not, shall be in writing and unless in writing shall not be valid, binding or be or any effect whatsoever.

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATED:

(12). The laboratory shall not be in any way interested in or concerned directly or indirectly with any of the officers, subordinates or servants of BPPI in trade, business or transactions nor shall the laboratory give or pay or promise to give or pay any such officer, subordinate or servant directly or indirectly any money or fee or other consideration under designation of custom or otherwise nor shall the laboratory permit any person or persons whomsoever to interfere in the management or performance thereof under power of attorney or otherwise without obtaining the consent of BPPI in writing.

BANKRUPTCY OF THE LABORATORY:

(13). In case the Laboratory at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of backrupcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the BPPI to put an end to the Agreement, and thereupon every article, clause and thing herein contained

to be operative on the part of the BPPI, shall cease and be void and the BPPI shall have all the rights and remedies given to him under the precedent clauses.

SERVING OF NOTICES TO LABORATORY:

- (14). All notices or communications relating to or arising out this agreement or any of the terms thereof shall be considered duly served on or given to the laboratory if delivered to him or left at his premises, place of business or above.
- (15). And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any Para herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of CEO, BPPI in the matter shall be final and binding on both parties.
- (16) All disputes under this Agreement shall be resolved as follows. Within 15 days after written notification of the dispute, principals or officers of Laboratory and BPPI shall meet in an effort to resolve the dispute. If the dispute remains unresolved, the parties shall participate in a facilitated mediation pursuant to the rules of the Indian Arbitration and Conciliation Act, 1996, Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI in accordance with the provisions of Arbitration Act, 1996.
- (17). In the event of any disputes between the parties the dispute would be subject to the jurisdiction of civil courts within Delhi only.
- (18) If any of the provisions of this agreement are held to be invalid or unenforceable in any respect, the remaining terms will remain effective and the agreement will be construed as if the invalid or unenforceable matters were never included in it. No waiver of any default will be a waiver of any future default. Neither party shall be liable for nonperformance caused in whole or in part by Acts of God, civil unrest and war.

In witness where the laboratory and CEO, BPPI acting for and on behalf of BPPI have set their hands the day, month and year written above.

Authorized Signature of BPPI Authorized Signature of Laboratory

Name Name & designation Address and Seal Address and Seal

Witnesses for BPPI Witnesses for Laboratory

Signature Signature Name Name Address Address

Proforma for Performance Statement

- (1). Name of Laboratory:
- (2). Address:
- (3). Performance Statement:

Sr. No.	Category	No. of sample analysis) tested	Total no. of Samples	
		2015-16	2016-17	
1	Tablets			
2	Capsules			
3	LVP / SVP			
4	Dry Powder Injectables (DPI)			
4	Liquid Orals/Syrups/Susp.			
6	Ointments/ Creams/ Gel/ Lotion			
7	Eye/Ear Drops / Nasal Drops			
8.	Vaccines & Sera			
9.	No of samples failed			

Note: Facilities for LAL test if available

Details of Laboratory and Certificate of Registration for Service Tax

(1).	Name of Laboratory
(2).	Address of Head Office, if any:
(3).	Address of Laboratory
(3).	Address of Laboratory
(4).	Name of contact person
(5).	Phone No.:
	Mobile No.:
(6).	E-mail:
(7).	Details of Approval/ License issued by Drugs Regulatory Authority*
(8).	Validity of Approval/ License issued by Drugs Regulatory Authority:
(9).	NABL Certificate No. along with discipline*
(10).	Validity of NABL Certificate:
(11).	Certificate of Registration for Service Tax: To be enclosed
(12).	Any other certificates with details*

* enclose duly attested copy

Personnel in Laboratory

- 1) Total qualified technical personnel engaged in Chemical / Instrumental analysis:
- 2) Total qualified technical personnel engaged in Microbiological analysis:
- 3) Details of Competent (Approved) staff by State Licensing Authority

S. No.	Name	Designation	Qualifications	Approval in Chemical / Instrumental/ Microbiological Testing	Experience in relevant analysis (Years)

ANNEXURE-III-B

<u>List of all functional Sophisticated Instruments/ Apparatus including used</u> <u>for testing of Insulin, vaccines & sera etc.</u>

S. No.	Name	of	Total Number	Make	Date	of
No.	Instrument/				Installation	
	Apparatus					

Enclose additional paper

Facilities in Microbiological Section with AHU in Laboratory

1) List of reference cultures available:

To be given

2) List of reference impurities available:

To be Given

- 3) List of reference standard/ working references available: To be Given
- 4) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)

S.	Name of	Total	Make	Date	of
No.	Instrument/	Number		Installation	
	Apparatus				

Enclose additional paper

Declaration Form (To be attested by Notary)

I / We _(Name of Bidder)	having our Head Office at
and Drug T	Testing Laboratory at do
hereby declare that I / we have careful	ly read all the conditions of the tender of Bureau of
Pharma Public Sector Undertakings of	India (BPPI), Gurgaon for empanelment of Drugs
Testing Laboratories for analysis of D	RUGS & MEDICINES for two year period (2017-
2019) and abide by all conditions said th	nerein.
I/We further declare that we have ve	alid approval/ license issued by Drug Regulatory
Authority bearing no	and NABL Certificate bearing no in
discipline	
Signature	
Name of Authorized Person Seal of Laboratory	

Annexure – VA

List of DRUGS for the Analysis of Medicines for THE YEAR 2017-2019

Sr. No.	Drug Code	Generic name of Drug	Unit Size	quoted by as symbol () yes
1	33	Amoxicillin 250 mg; Lactic Acid Bacillus 60 MU Capsules	10's	
2	34	Amoxycillin 500mg + Bromhexine 8 mg Capsules	10's	
3	46	Ampicillin Injections I.P. 500mg	Vial & WFI	
4	51	Cefadroxil film coated Tablets IP 250mg	10's	
5	67	ceftazadime 1000mg injection	Vial with WFI	
6	68	Ceftazadime 250mg Inj.	Vial with WFI	
7	69	Ceftazadime 500mg Inj.	Vial with WFI	
8	72	Ceftriaxone + Tazobactum 250 mg + 31.25 mg Inj.	Vial with WFI	
9	88	Co-trimoxazole (Sulphamethoxazole 200mg + Trimethoprim 40mg / 5ml) Susp	50ml bottle	
10	90	Co-trimoxazole-Pead. Tab. (Sulphamethoxazole 100mg+Trimethoprim 20mg) Tablets	10's	
11	93	Erythromycin Stearate 250mg film coated Tablets	10's	
12	99	Norfloxacin 400mg film coated Tablets	10's	
13	107	Tinidazole 300mg film coated tablet.	10's	

14	113	Beclomethasone 0.025%+ Neomycin 0.5% w/wCream	15g tube	
15	114	Beclomethasone Dipropionate 0.025% w/v Oint.	15g tube	
16	116	Chlorhexidine Gluconate 5% Solution	500ml bottles	
17	118	Clobetasol Propionate 0.05 % w/w Cream	15g tube	
18	122	Ketoconazole 2% w/w Lotion	100ml Bottle	
19	123	Lignocaine 2% w/w Ointment	30 g tubes	
20	130	Chlorhexidine 1.5%w/v +Cetramide 3%w/v Solution	100ml Bottle	
21	146	Pioglitazone 15mg tablet	10's	
22	148	Pioglitazone 15mg + Glimeperide 1mg Tablets	10's	
23	149	Pioglitazone 15mg+ Glimeperide 2mg Tablets	10's	
24	151	Dihydroergotamine 1mg film coated Tablets	10's	
25	157	Etoposide 100mg Caps	10's	
26	161	Medroxyprogestrone Acetate 10 mg film coated Tablets	10's	
27	162	Raloxifene 60 mg Tab	10's	
28	166	Dextrose 10% (10D) Injections	500 ml bottles	
29	167	Dextrose 5% (5 D) Injections	500 ml bottles	
30	168	Glucose Normal Saline (DNS) solutions	500 ml bottles	
31	171	Mannitol 20% Infusion IP	350ml	
32	173	Normal Saline (NS) solutions	500ml	
33	182	Dicyclomine 20mg+ Mefenamic Acid 250 mg Tabs	10's	
34	184	Dicyclomine Hcl20mg+Paraceatmol325mg tablet	10's	
35	185	Diethylcarbamazine citrate 100mg film coated Tablets	10's	
36	204	Norfloxacin 100mg+ Metronidazole 100mg/5 ml Syrup	30ml bottle	
37	205	Ofloxacin 50mg+ Metronidazole 100mg/5ml Syrup	30ml bottle	
38	226	Iron (Carbonil Iron) 100mg + Folic Acid 1.5mg + Zinc Capsules	15's	
39	228	Iron Tonic Carbonil Iron 100mg + Folic Acid 1.5mg + Zinc each 5ml Syrup	200 ml bottles	

40	236	Budesonide 100mcg Rotacaps	30 Rotacaps	
41	237	Budesonide 200mcg Rotacaps	30 Rotacaps	
42	238	Budesonide 200mcg/dose Inhaler	200md	
43	249	Levocetrizine HCl 5mg +Pseudoephedrine	10's	
43	243	20mg+ Paracetamol 325mg Tablets	103	
44	255	Salbutamol 100 mcg/puff Inhaler	200 md	
45	257	Salbutamol 2.5mg Respule	2.5ml	
46	258	Salbutamol 200mcg Rotacaps	30's	
47	261	Adenosine 6 mg/ 2ml Amp.	2ml	
48	262	Amiodarone 100 mg Tabs	10's	
49	268	Clonidine 0.1 mg Tabs	10's	
50	272	Diltiazem 60mg Tablets	10's	
51	284	Isosorbide Mononitrate 10mg Tabs	10's	
52	292	Nifedipine 10mg Capsules	10's	
53	297	Tamsulosin Hydrochloride 0.4 mg Capsules	10's	
54	303	Artesunate 50mg Tabs	10's	
55	305	Chloroquine Phosphate 250 mg film coated Tablets	10's	
56	307	Primaquine 2.5 mg film coated Tablets	10's	
57	308	Primaquine 15 mg film coated Tablets	10's	
58	309	Sulphadoxine 250mg+Pyrimethamine 12.5mg/5ml Syrup	10ml bottles	
59	310	Sulphadoxine 500 mg +Pyrimethamine 25mg Tablets	10's	
60	315	Betahistine 16mg Tablets	10's	
61	332	Thyroxine Sodium 100 mcg Tablet	100's	
62	339	Betaxolol Hydrochloride 0.5 % w/w Eye Drop	5ml	
63	340	Acyclovir 3% w/w Eye Onitment	5 gm	
64	342	Chloramphenicol 0.5 % w/v Eye Drop	5ml	
65	343	Chloramphenicol 1%w/v Eye Applicaps	100 Applicaps	
66	346	Ketorolac Tromethamine 0.5 % w/v Eye Drop	5ml	
67	347	Prednisolone Acetate 1 % w/v Eye Drop	5ml	
68	350	Timolol Maleate 0.5 % w/v Eye Drop	5ml	
69	353	Ketamine Hydrochloride 10mg/ml Inj.	10ml	
70	354	Ketamine Hydrochloride 50mg/ml Inj.	2ml	
71	355	Lignocaine 1% w/v Inj.	20ml Vial	

72	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ml Vial	
73	363	Insulin Glargine 100 IU Injections	Cartridge/Vial 3ml	
74	364	Glimepiride2mg+MetforminHydrochloride 500mg SR tablet	15's	
75	365	Gliclazide80mg+MetforminHcl tablet500mg	15,s	
76	367	Voglibose tablet 0.3mg	10,s	
77	368	GLICLAZIDE TABS/CAPS SR 60MG	10's	
78	369	Acarbose tablet IP 50mg	10,s	
79	372	Metformin Hydrochloride Tablets IP Prolong Release 500 MG	10's	
80	377	Clindamycine capsule IP 300mg	10,s	
81	378	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG ETHAMBUTOL TABLET IP 800MG AND PYRAZINAMIDE TABLETS IP 750MG	1's	
82	379	Rifampicin and Isoniazide Tablets IP (450 MG+300 MG)	10's	
83	387	Tebinafine tablet250mg	7,s	
84	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	
85	389	Penicillin G Pottasium Tablets 400000 U	6's	
86	392	GRISEOFULVIN TABLETS IP 250 MG IP	10's	
87	393	ACYCLOVIR 800MG DISPERSIBLE TABLETS IP	5's	
88	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML IP	10ml	
89	397	Oxytetracycline Cap I.P 250 MG	10's	
90	399	RIFAMPICIN 100MG, ISONIAZIDE 50MG and PYRAZINAMIDE 300MG TABLETS IP	10's	
91	412	AZATHIOPRINE TABLETS IP 50 MG	10's	
92	413	METHOTREXATE TABLETS IP 7.5 MG	10's	
93	415	GLYCERYL TRINITRATE TABLETS IP 2.6 mg	25's	
94	416	Prazosin Tablets IP 5 mg	15's	
95	417	TELMISARTAN 40 mg + AMLODIPINE 5 mg TABLETS	15's	
96	419	HEPARIN SODIUM 50 IU, Benzyl Nicotinate 2mg/gm Cream	20gm	
97	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG CAPSULES	10's	
98	421	NEBIVOLOL TABLETS IP 5 MG	10's	
99	422	Torsemide Tablets 10 MG	15's	

100	423	Bisoprolol Tablets 5 MG	10's	
101	424	Carvedilol Tablets IP 3.125 MG	10's	
102	425	DILTIAZEM TABLETS SR 90 MG	10's	
103	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	
104	430	AMIODARONE Tablets IP 200 mg	10's	
105	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	
106	437	Nifedipine Prolonged Release Tablets IP 20MG	10's	
107	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	
108	439	OLMESARTAN MEDOXOMIL 40mg + HYDROCLORTHIAZIDE 12.5mg Tablets	10's	
109	440	Metoprolol 50 MG + Amlodipine 5 MG Tablets	7's	
110	441	Losartan 50mg+Amlodipine 5mg tablet	10,s	
111	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	
112	444	Enalapril 10 MG + Hydroclorthiazide 25 MG Tablets	30's	
113	445	OLMESARTAN 20mg+ AMLODIPINE 5mg Tablets	10's	
114	450	Labetalol tablet IP 100mg	10,s	
115	452	Warfarin tablet IP 5 mg	10,s	
116	455	Verapamil tablet IP 80 mg	10's	
117	456	Atorvastatin tablet IP 40mg	10,s	
118	467	DICYCLOMINE 10 mg+ MEFENAMIC ACID 250 mg Tablets	10's	
119	472	Domperidone 30mg+ Esomeprazole 40mg tablet	10,s	
120	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	
121	479	TRICHOLINE CITRATE 550MG + SORBITOL 7.15GM SYRUP/10ML	200 ML	
122	483	LOPERAMIDE Capsules IP 2mg	10's	
123	488	LANSOPRAZOLE CAPSULES IP 15MG	10's	
124	491	ITOPRIDE Tablets 50mg	10's	
125	492	Sulfasalazine Tablets EC BP 500 MG	10's	
126	493	Ispaghula Husk IP 50GM	50 GM	
127	494	Ispaghula Husk IP 100GM	100gm	
128	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	
129	500	LEVO-THYROXINE TABLETS IP 100MCG	100's in A Bottle	
130	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	1ml	

131	505	CARBIMAZOLE TABLETS IP 10mg	100's in Bottle	
132	507	CARBIMAZOLE TABLETS IP 5 MG	10's	
133	516	ACECLOFENAC Tablets SR/CR 200 mg	10's	
134	517	THIOCOLCHICOSIDE 4 mg+ ACECLOFENAC 100 mg Tablets	10's	
135	518	BACLOFEN Tablets IP 10 mg	10's	
136	519	Ketorolac tablet DT 10 mg	10's	
137	521	TRAMADOL TABLETS SR 100 MG	10's	
138	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL	
139	531	GUAIFENESIN 100mg+ TERBUTALINE 2.5mg+ BROMHEXINE 8mg/10ml SYRUP	100ml Bottle	
140	532	Fluticasone 250MCG, Salmeterol 50mcg/Rotacap	30 Rotocaps	
141	534	Beclomethasone Dipropionate 200 MCG, Salbutamol 400 MCG Rotacap	30 Respicap	
142	539	ACETYLCYSTEINE Tablets 600mg	10's	
143	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2ml	
144	556	MONTELUKAST 10MG + FEXOFENADINE HCI 120MG TABLETS	10's	
145	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MDI	
146	566	IPRATROPIUM 250 MCG/ML SOLUTION	15ml	
147	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	
148	568	Salmeterol 50 Mcg, Fluticasone Propionate 250 Mcg/1 Dose Inhaler	120 MDI	
149	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	
150	581			
151	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	
152	589	Calcium Citrate Maleate 500MG & Calcitriol 0.25mcg Capsules	15's	
153	591	METHYLCOBALAMIN 500MCG INJECTION	1ml	
154	594	Glucose Powder	75gm	
155	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15ml	
156	598	PREGABALIN 75 mg+ METHYLCOBALAMIN 750mcg Tablet SR	10's	
157	599	PREGABALIN TABLETS 75MG	10's	

158	607	Beclamethasone Dipropionate0.025% w/, Neomycin 0.5% w/w (3500 Unit /G) Chlorocresol 0.1% w/w cream	15 GM	
159	609	Silver Nitrate0.20%w/w,Chlorhexidine gluconate solution 0.20%,presrvative chlorcresol0.12%w/w	15gm tube	
160	611	Cyproheptadine Hydrochloride(anhydrous) IP. 2 mg in a flavoured syrup	200ml	
161	616	Celecoxib 100mg capsules	10's	
162	617	Celecoxib 200mg capsules	10's	
163	622	Cough lozenges Ginger / Lemon (2,4 Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in Ginger /Lemon flavour	1's	
164	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	1's	
165	628	Etophylline IP 231mg. + Theophylline 69mg Tablet	10's	
166	629	Inhalent Softgel Caps. (Camphor 25 mg + Clorothymol 5 mg + Eucalyptol 130 mg + Menthol 55 mg + Terpineol 110 mg)	10's	
167	631	Ethamsylate B.P 500 mg	10's	
168	632	Ethamsylate B.P 250 mg	10's	
169	634	clobetasol Propionate 0.05 % w/w Neomycine sulphate 0.50%, miconazole nitrate 2.0%w/w, Chlorcresol0.10% IP Cream	20gm tube	
170	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200ml	
171	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	100ml Bottle	
172	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	200ml	
173	665	B Complex with vitamin C Each capsule contains - Thiamine mononitrate IP- 10mg,Riboflavin IP -10 mg,Pyridoxine HCl IP- 3mg,Vitamin B 12 IP - 5mcg,Niacimnamide IP - 50mg,Calcium Pantothenate IP-12.5mg,Flolic Acid IP -1mg, Ascorbic Acid IP- 150mg	10's	
174	668	Multivitamin Drops: Vitamin A(as Palmitate)IP 2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine Hydrochloride IP 1mg,Riboflavine Sodium Phosphate IP 1.5mg,Niacinamide IP 10mg,D-Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine	15ml	

175	673	Biotin 10mg Tablet	10's	
176	677	Flupentixol 0.5 mg Tablet IP	10's	
177	678	Levodopa & Carbidopa tab (250 mg + 25 mg) Tab. IP	10's	
178	679	Nalidixic Acid 500 mg Tablet IP	10's	
179	681	Phenazopyridine Hcl 100mg tab	10's	
180	684	Pantoprazole 40mg + Domperidone 30mg S.R. Capsules	10's	
181	687	Lactulose10 gm/15ml	200ml	
182	693	Tropicamide 1% Eye Drops IP	5ml	
183	695	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg Phenylmercuric nitrate 0.001% Eye drops IP	5ml	
184	696	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg ,Dexamethasone sodium phosphate IP 1 mg Phenylmercuric nitrate 0.001% Eye drops IP	5ml	
185	700	Ketamine Hydrochloride Injection IP 50 mg/ml	20ml Vial	
186	701	Pilocarpine Eye drop IP 2 %	10 ml Vial	
187	702	Haloperidol Tablet IP 0.5 mg	10's	
188	705	Levofloxacin Infusion IP 500mg	100ml Bottle	
189	707	Piroxicam Capsules IP 10 MG	10's	
190	708	Piroxicam 20 mg tablets	10's	
191	714	Ofloxacin 200mg+Ornidazole 500mg infusion	100 ML	
192	717	Etodolac tablets 300mg IP	10's	
193	721	Sterile Water for Injection I.P. Amp Polypack	2ml	
194	722	Sterile Water for Injection I.P. Amp Polypack	5ml	
195	725	Dextrose Injection IP 5 %, i.v fluid plastic container using FFS technology	500ml	
196	726	Dextrose Injection IP 10 %, i.v fluid plastic container using FFS technology	500ml	
197	728	Sodium Chloride (0.9% W/V) and Dextrose 5% w/v Injection IP,i.v fluid plastic container using FFS technology	500ml	
198	732	Sodium Chloride Injection IP 0.9%w/v(Normal Saline (NS) 0.9% w/v),i.v fluid plastic container using FFS technology	100ml	
199	755	Povidone Iodine Medicated paint 10 %	50ml bottle	
200	767	Metformin 1000mg SR +Glimepiride 2mg tablet	10,s	

201	793	Atenolol tablet 25 mg	14,s	
202	840	Citicoline tablet 500 mg	10''s	
203	863	Dextrose injection IP 25%	100ml	
204	889	Febuxostat tablet iP 80mg	10's	
205	904	Glimepiride 1mg +Metformin SR 500 mg tablet	10's	
206	968	Mitrazapine tablet 15mg	10's	
207	975	Nebivolol 5 mg, Hydrochlorothiazide 12.5 mg Tab.	10's	
208	976	Nebivolol Tablets IP 2.5mg	10's	
209	978	Nepafenac 0.1% w/v Eye Drop	5ml	
210	980	Nicorandil PR Tablets I.P 10mg	10's	
211	974	Natural Micronised progestrone Capsules	10's	
212	1012	Piracetam tablet400mg	10's	
213	1026	Propanolol tablet IP 10mg	10's	
214	1046	Salmetrol 50mcg +Fluticasone Propionate 250mcg/1 doseMultihaler Mdi	120mdi	
215	1050	Sertraline tablet IP 100mg	10's	
216	1074	Telmisartan 80mg +Hydrchlothiazide 12.5 mg	10's	
217	1098	Voglibose 0.2mg+Metformin 500 tablet	10's	
218	1106	Telmisartan 40mg +Metoprolol 50mg Tablets	10's	
219	1107	Pregabalin Capsules 75mg	14's	
220	1108	Sildenafil Tablets 100 mg	4's	
221	1109	Prazosin Tablets 2.5mg	30's	
222	1110	Clobazam Tablets 5mg	10's	
223	1111	Gabapentin 400mg + Nortriptyline 10mg Tablets	10's	
224	1112	Cinnarizine Tablets 25mg	10's	
225	1113	Pioglitazone Tablet IP Strength 7.5 mg	10's	
226	1114	Moxifloxacin Hydrochloride Sterile Ophthalmic solution 0.5% w/v	5ml	
227	1115	Gatifloxacin Hydrochloride Sterile Ophthalmic solution 0.3% w/v	5ml	
228	1116	Ciprofloxacin Hydrochloride Sterile Ophthalmic ointment 0.3%	3gm	
229	1117	Loteprednol Etabonate Sterile Ophthalmic suspension 0.5% w/v	5ml	
230	1118	Moxifloxacin Sterile eye ointment 0.5% w/w	5gm	
231	1119	Moxifloxacin 0.5% w/v and Dexamethasone 0.1%w/v Sterile Eye drops	5ml	
232	1120	Gatifloxacin 0.5% w/v and Dexamethasone 0.1%w/v Sterile Eye drops	5ml	
233	1121	Ciprofloxacin 0.3 % w/v and Dexamethasone 0.1%w/v Sterile Eye drops	5ml	

234	1122	Chloramphenicol 1 % w/v and Dexamethasone 0.1%w/v Sterile Eye drops	5ml	
235	1123	Clomipramine Hydrochloride SR Tablets 75mg	10's	
236	1124	Fluvoxamine Hydrochloride Tablets 100mg	10's	
237	1125	Aripiprazole Tablets 5mg	10's	
238	1126	Mecobalamin 1500mcg, Alpha lipoic acid 100mg, Benfotiamine 100mg, Vitamin B6 3mg, Folic acid 1.5mg Capsules	10's	
239	1127	Human Albumin Solution 20%	50 ml	
240	1128	Fenofibrate Tablets 145 mg	10's	
241	1129	TENELIGLIPTIN 20MG + METFORMIN 500 MG Tablet	10's	
242	1130	TENELIGLIPTIN 20mg + METFORMIN 1000mg Tablet	10's	

Annexure- VB- List of Surgical items

		List of Surgical items		
1 Sr. No.	2 Item Code	3 Name and description of Items	4 Unit Size	quoted by as symbol () yes
1	5001/5002/5003	Absorbent Cotton Wool I.P. 75 /200/500 gm (Non Sterile)	1's	
2	5004/5005	Crape Bandage B.P. 15 cmX4 meter/10cmx4meter	12	
3	5006/5007/5008	Cotton Bandages(Non Sterile), Size 7.5 /10cm/15cmcmX4M as per Schedule F-II	1X12	
4	5009	Adhesive Bandages Washproof 19 mmx72 mm or 19mm X 70 mm containing Benzalkonium Choride Solution IP eq. to Benzalkonium Chloride 0.5%W/W	1's	
5	5010/5011/5012/5013/5014/5015/5016/5017/5018	Sterile Hypodermic Syringe with Needle attached, , Single use- different sizes, IS 12050 (Sterile, single use, disposable, as per BIS/CE Certified)]	1's	
6	5073	Crepe Bandage B.P. 6 cmX4 meter	12	
7	5074/5075/5076	A.V.Fistula Needle (Pair)15/16/17G	1's	
8	5077	Malaria antigen pan/tester P.f. Test Kit	1's	

9		5078	Dengue Antigen (NS1) Test Kit	1's
10		5079	HCG -Pregnancy Card Test Kit	1's
11				
12	5080/5081/5082		Sterile Disposable Spinal Needle for Single Use 23/26/27G x 3 ½ inch	1's
13		5083	Ear buds 100% COTTON ,IDEAL SIZEFOR CLEANING	60 swab
14	5084/5085/5086/5087/5088/5089/5090		Surgical Blade, Sterile, different Size Single peel pack in metal foil, be smooth and free from tool marks and any sign of corrosion.	1's
15	5091/5092/5093		Micropore Surgical PAPER TAPE ALL SIZE	6rolls/box
18	5094/5095/5096		sterile gauze pad size 2"X2"/3x3/4x4	10's
19		5097	Alcohol Swab (Spirit Swab)	1's
20	6050/6051/6052		Knee Cap Small/medium /large	pair
21		6053	Disposable Sterile Surgical Rubber Gloves, Size 6 ½ Inches, Conforms to IS 13422,ISI marked / CE certified / FDA approved	Pair
22		7001	Hot water Bag SIZE 25.5cmx17.8cm(10"x7")BS:1970:2012	1's
23		7002	Clinical Thermometer As per IS 3055 (Part-1) Specification/CE certified, GLASS	1's
24	8085/8086		Oxygen Mask, Size: Paed/adult	1's
25		8087	Automatic Snap-Out Folding Walking Cane Stick with Adjustable Length - Color: Copper Easy & Quick to Use Walking Cane for Treks, Casual Walks or Outdoor Travel.	1's
26			Release The Stick and 4 Folding Sections Snap Out Automatically to Make a Rigid Cane.	
27			Lightweight Anodized Aluminum Pole. Contour Grip Handle with Rubber Bottom.	
28			Sections Folds Conveniently In Its Own Wallet. Adjustable Length: 33 inch to 37 inch.	
29			Package Contains 1Pc Adjustable Metal Walking Cane.	
30		8088	Walking Stick with three supporter- light weight length 33 inch to 37 inch	1's

31	8089/8090/8091/8092/8093/8094	Abdominal Belt Velcro after surgery or after delivery to support abdominal region Cream color - Large /medium/small	1's	
32	8095/8096/8097/8098	Anklet Binder Valcro pair Soft patella, Dual grip, Four way stretchable fabric, Controlled compression, Convenient application Size Small/medium/large	1's	
33	8099/8100/8101/8102	Cervical Collar -designed to meet the needs of ambulatory patients over and extended time. Technologically advanced Sorbatex padding adds long term comfort by quickly absorbing moisture away from the skin. Anatomical shape, Wellventilated, High density PU foam, Skin matching shades, Hypoallergenic covering Small/medium/large	1's	
34	8103/8104/8105/8106	Thumb and Wrist brace - Soft Neoprene thumb cover • Pre-shaped and removable metal stays for wrist and thumb • Distal brace edge situated under the palmar crease • Brace is contoured at the ulnar aspect of the hand • Elastic material • High coverage of dorsal aspect of the hand • Reliable thumb support • Convenient application Small /medium/large	1's	
36	8107/8108/8109	Knee Brace Belt - Excellent Support and Targeted Pain Relief • May Relieve the Pain Associated with Mild Osteoarthritis (OA) of the Knee • Unilateral Hinge and Strapping Configuration Apply Corrective Force to Offload the Affected Side of the Joint • Wrap-Around, Patient-Friendly Design - Easy to Apply to Swollen Tender Knees • Neoprene Provides Therapeutic Warmth to Soothe the Aching Joint • Support Straps Allow for Adjustable Compression • Available in Medial and Lateral Designs for Left and Right Knee Applications • Interchangeable Condyle Pads for Day-to-Day Adjustment Sizesmall/medium/Large	1's	

37	8110/8111/8112	UROMETER - Three Chamber system Measuring glass capacity: 400ml	1's	
38		Urine collection bag for convenient drainage of urine.,Inlet tube 120cm-170cm		
39		Sampling Port (needleless), Bed- Sheet Clamp, Drainage control knob effectively drains urine., Hanger& string for convenient and firm fixing of the urine meter to the upper side frame of the bed, Anti-reflux drip chamber., Exact and fine scaling for timed measurements, Urine sampling points at connector and measuring glass, Germs and liquid tight, hydrophobic coated filter for pressure equalisation		
40		Long, highly flexible and bend- protected tube, Single hand, easily operated outlet valve, Sterile by ETO		
41		Urine collection bag for convenient drainage of urine.,Inlet tube 120cm- 170cm		
42		Sampling Port,Bed-Sheet Clamp,Drainage control knob effectively drains urine.		
43		Hanger & string for convenient and firm fixing of the urine meter to the upper side frame of the bed.,Antireflux drip chamber.,Exact and fine scaling for timed measurements,Urine sampling points at connector and measuring glass		
44		Germs and liquid tight, hydrophobic coated filter for pressure equalisation		
45		Long, highly flexible and bend- protected tube, Single hand, easily operated outlet valve, Latex Free, Sterile by ETO		
46	8113	Hernia Belt - made from good quality surgical Elastic with elasticated straps, pads can be adjusted. Size Universal (SIZE : Small/Medium/Large)	1's	
47	8114	E.C.G ElectodesLiquid gel system, Long time duration,Foam/ Aggressive, Dimension (HxWxT) 50X48X1 mm	1's	
48	8115	Vacuum Extractor Set, manual operated.Complete with 3 stainless	1's	

49	8116	steel cups (40, 50, 60mm). Autoclavable Silicone pressure tube, Traction handle.Suction pump, glass jar fitted between M.S. Basket with vacuum gauge and control valve. IV Cannula Fixer Good aesthetic appeal due to woven fast edges, Moisture responsive High Moisture vapour Transmission rate Film, Low allergy grid pattern adhesive, Porous adhesive to allow skin breathing, Easy and Painless remove, because of thin- non adhesive edges and leaves no residue after remove.Medium: 6cm x 5cm	1's	
50	8117	Cervical Pillow- Designed to decrease morning pain and stiffness, Height 12.3 Centimeters, Length 20.3 Centimeters, Width 3.08 Meters, Weight 680 Grams, Material Polyester, Shell Soft	1's	
51	8118/8119/8120	Sample Blood Collection Needles With Hub with optical venipuncture control can make an important contribution to simplifying blood collection routine for phlebotomists. The needle has a transparent plastic hub, which functions as a view window. If venipuncture is successful, the view window is coloured red due to the blood flow.different sizes.	12 set	

Annexure – VI **Ref. Clause no. 2 (e), 5. vi**

Declaration

I	Ma	anaging	Director/Par	tner/Propriet	or of	M/s
					_	
office at						
do hereby declar deregistered/ei Organization or i tender no	ther by any its drug procur	state C	Government	or central	Gove	rnment
				M/s	•••••	•••••
				(Compai	ny Seal

To be attested by Notary

CHECK LIST

S. No.	Particulars	Page No.	Yes	No
1.	Annexure VI - Checklist			
2	EMD in the form of DD shall be kept in an envelope.			
3	Self attested and notorised Photo copy of licence for Drug			
	Testing Laboratory renewed upto ate.			
4	Recognition Certificate issued by NABL & its renewal			
5	Annual Turn over for the last two years certified by the auditors. i.e. 2014-2015 & 2016-2017 certified by the auditors.			
6	GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 (Schedule L1 certificate.			
7	Certificate for analysis issued by other recognized agencies			
8	Non conviction certificate as per pera 3(e)			
9	Annexure – I Proforma for performance statement			
10	Annexure – II Details of Laboratory and Certificate of Registration for service tax			
11	Annexure – III (A) Personnel in Laboratory.			
12	Annexure – III (B) List of Sophisticated instruments.			
13	Annexure – III (C) Facilities in Microbiological section			
14	1) List of reference cultures available:			
15	2) List of reference impurities available:			
16	3) List of reference standard/ working references available			
17	Annexure – IV Declaration form duly signed & notarized.			
18	Annexure – VA List of DRUGS Annexure – VB List of Surgical			
19	Annexure – VI Declaration as pera 2(e			
20	Documentary evidence, for the constitution of the company / laboratory ie., Memorandum and articles of Association or partnership etc.,			
21	The instruments such as power of attorney, resolution of board etc.,			
22	The tender document signed by the tenderer in all pages with official seal			
23	Documentary evidence of having analyzed drugs for the test for the last two years			
24	Whether lab engaged in mfg activities (If yes, give details)			
25	Cover B: Annexure – VII (Price Bid) Hard and softcopy in a separate cover			

Price Bid For Drugs

S. No.	Drug Code	Name of Medicine	Unit Size	Rate excluding Tax(Rs)	Tax applicable in %	Total including Taxes(Rs)	Remarks
1							
2							
3							
4							
5							
6							
7							

Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.

Annexure – VIIIB

Price Bid For Surgical

S. No.	Drug Code	Name of Medicine	Unit Size	Rate excluding Tax(Rs)	Tax applicable in %	Total including Taxes(Rs)	Remarks
1							
2							
3							
4							
5							
6							
7							

Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also